drugset / Trial / NCT04133116
A Study of LY3471851 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 7 weeks for each participant.
Timeline
- Start
- 2019-10-29
- Primary completion
- 2020-03-06
- Completion
- 2020-03-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rezpegaldesleukin | Protein / enzyme biologic | 450 ug | Subcutaneous |
| Subject | Rezpegaldesleukin | Protein / enzyme biologic | 900 ug | Subcutaneous |
| Subject | Rezpegaldesleukin | Protein / enzyme biologic | 1800 ug | Subcutaneous |
Indications
No indication recorded.